ANDA Stress Test: End-Of-Year Submission Bolus Pressures US FDA Review System
As more generic applications arrive, Office of Generic Drugs staff may have a tougher time reaching review goals.
You may also be interested in...
US FDA Might Be Temporarily Headed By Ostroff As Califf Sets His Departure
Former acting commissioner in line for the temporary position again under FDA policy, unless incoming Trump administration designates someone else.
Generic Application Quality Showing Signs Of Improvement
US FDA’s monthly refuse-to-receive numbers for ANDAs are down early in FY 2017, suggesting that sponsor have an increased understanding of the agency’s standards.
ANDA Submission Wave Continues; Is A Crest Near?
Sponsors continue to submit generic drug applications at elevated rate for second-straight month as approvals increase.